Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetic study of HP-3060 in pediatric patients with allergic rhinitis
jRCT2080223009Phase 2
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of HP-3060 in allergic rhinitis (AR), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoint: Primary pharmacokinetic endpoints.
02
Drugs
HP-3060
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080223009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223009.